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published utility values exist. METHODS: Consecutive outpa-
tients with non-small cell lung cancer (NSCLC) attending a major
Canadian cancer centre completed the EORTC QLQ-C30 and
EQ5D on a single visit. Different patient disease states included:
1) relapse-free post-resection, including on preventive chemo-
therapy; 2) in relapse, including on palliative chemotherapy or
targeted therapy (erlotinib); and 3) on chemoradiation for locally
advanced NSCLC. Exploratory correlation of EORTC QLQ-C30
and EQ-5D scores is ongoing. RESULTS: A total of 172 patients
participated. The median age of the sample was 65, (range 32–85
years); 47% were male. Half had advanced NSCLC (51%), 41%
were relapse-free post-resection, and 8% had locally advanced
NSCLC. Nearly half of relapse-free patients received preventive
chemotherapy. Twenty-seven percent of advanced NSCLC
patients were receiving palliative chemotherapy, 35% targeted
therapy with erlotinib, and the rest were not on active treatment.
Utility values (based on the EQ5D) were not signiﬁcantly different
among groups, including by disease status (relapse-free versus
in relapse), and current treatment (chemotherapy, erlotinib or
observation). Mean utilities were similar for relapse-free patients
despite treatment, 0.76, and minor differences were seen among
those in relapse, (on chemotherapy, mean utility 0.69; on erlotinib
0.77, on supportive care, 0.75). Exploratory correlation of
EORTC QLQ-C30 and EQ5D values will be presented. CON-
CLUSIONS: QL values in the derivation of patient utility for
different health states in clinical trials may further the ability to
estimate cost utility of novel therapies in cancer clinical trials.
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OBJECTIVES: Intravenous bisphosphonate use in cancer
patients is associated with exposed and necrotic jaw bone, called
Osteonecrosis of the Jaw (ONJ). The overall aim of this pilot
study was to develop a survey that captured the oral health-
speciﬁc and the global health related quality of life (HRQoL)
impact of ONJ, to test the feasibility of survey instruments and to
assess subject distress. METHODS: A 30 minute phone survey
was created with multi-disciplinary collaboration. Four stan-
dardized ONJ health states were developed and subjects’ prefer-
ences (utility) for each state were obtained using the Visual
Analogue Scale (VAS), the EQ5D and time-tradeoff (TTO) ques-
tions. A Visual Basic Interface was constructed to guide the
interviewer through TTO questions designed for the survey. The
subject’s life before and after ONJ was evaluated with the Oral
Health Impact Proﬁle (OHIP). Emotional discomfort during and
after survey was evaluated on a ﬁve point Likert scale. Subjects
were randomly identiﬁed from a cohort of 80 cancer patients
with ONJ. RESULTS: The pilot study included ﬁve patients
(response rate = 100%). Utility decreased with increasing ONJ
stage for all HRQoL instruments: 0.76, 0.97, 0.86 (Cancer and
No ONJ), 0.72, 0.88, 0.83 (Cancer and Stage 1 ONJ), 0.43,
0.52, 0.63 (Cancer and Stage 2 ONJ) and 0.34, 0.39, 0.56
(Cancer and Stage 3 ONJ) for VAS, EQ5D and TTO respectively.
With a baseline mean of 1.6, the OHIP score increased to 7.2
after ONJ (0–28 scale). Two subjects ranked 2 (“a little”) for the
level of emotional discomfort during the survey, but none were
upset afterwards. CONCLUSIONS: Based on preliminary
results, the study design was feasible and both oral health-speciﬁc
and global HRQoL instruments were sensitive to QoL changes
associated with ONJ. All HRQoL instrument performance
showed appropriate rank ordering and consistent relationship by
ONJ stage. There was minimal subject distress.
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OBJECTIVE: To compare the valuation of ovarian cancer health
states as assessed by the visual analog scale (VAS) and the stan-
dard gamble (SG). METHODS: Ovarian cancer patients and
oncologists were enrolled in this study. Participants were asked to
score six hypothetical treatment scenarios using the VAS and SG.
Values were compared using the intraclass correlation coefﬁcient
(ICC) and t-test. RESULTS: Fifty-one patients and 34 oncologists
were enrolled to this study. Participants were asked to rank order
health states in a one-time interview using the VAS, followed by
assessment of the health states, in random order, using the SG.
This resulted in 244 and 199 SG-VAS data pairs for analysis from
patients and oncologists, respectively. The ICC among patients
was 0.003 (95% CI: -0.122 to 0.129; F-test, p = 0.479). A
signiﬁcant difference was observed between VAS and SG scores
for patients receiving chemotherapy (mean difference, -0.114,
p < 0.0001), but not for patients under surveillance (mean dif-
ference 0.06, p = 0.13). The SG produced higher valuation than
the VAS among patients receiving chemotherapy, but the VAS
produced higher values than the SG among patients under sur-
veillance. For oncologists, the ICC was 0.323 (95% CI: 0.192 to
0.442; F test p < 0.0001), with the SG 0.09 higher than VAS
values (p < 0.0001). Each patient group valued the health states
in the mean range of 0.46–0.61 on the VAS; however, SG utilities
ranged from 0.53–0.61 for patients receiving chemotherapy and
from 0.30–0.37 for patients under surveillance. The range of
mean values by oncologists was 0.27–0.66 and 0.30–0.70 for the
VAS and SG, respectively. CONCLUSION: There appear to be
different utility values obtained using the SG and VAS among
patients undergoing treatment, patients under surveillance, and
oncologists. This comparison suggests the importance of consid-
ering differences between these groups and method used when
conducting utility valuation research in ovarian cancer.
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OBJECTIVE: Patients with breast and colorectal cancer can use
oral and injectable chemotherapy treatments. The objective of
this study is to assess the satisfaction in patients using capecit-
abine (oral chemotherapy) in comparison with their previous
experiences with injectable chemotherapies. Also, we aimed to
compare the preference of patients on this oral drug to the
injectable chemotherapy treatments. METHODS: Quantitative
study performed with 150 oncology patients with breast and
colorectal cancer (from all Brazilian regions) who use capecitab-
ine as a treatment. A structured questionnaire with 10 answers
assessing six attributes was used. RESULTS: The average age of
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the patients is 61 years, with these patients presenting cancer for
an average of 4 years. Eighty-nine percent of the patients use
capecitabine as monotherapy, and the rest use it combined with
injectable treatments. Comparing capecitabine with injectable
regimens, 89% of the studied subjects prefer the oral treatment.
Capecitabine is best evaluated than the injectable treatments in
the attributes: practicability, freedom, quality of life, efﬁcacy and
side effects. Treatments were assessed in a similar way about the
item cost. Approximately third quarters consider capecitabine as
efﬁcient; such rate is slightly higher than the observed for inject-
able chemotherapy: 75% vs. 58%. CONCLUSION: Capecitab-
ine is largely approved by its users, with 89% of them preferring
it in comparison with the injectable treatments. The oral chemo-
therapy has as positive differences, in the perception of its users,
practicability and freedom.
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OBJECTIVE: Elderly patients are underrepresented in oncology
trials and may be at higher risk of toxicity with less than optimal
quality of life compared with younger patients. The Phase III
TARGET clinical trial showed that sorafenib signiﬁcantly pro-
longed progression-free survival (PFS) compared with placebo
(P < 0.000001) in patients with advanced renal cell carcinoma
(RCC). This retrospective analysis of sorafenib in advanced
RCC patients from the pivotal TARGET trial compared patient
reported outcomes (PRO) in young and elderly patients.
METHODS: This subgroup analysis examined the PRO in
elderly (>=70 years of age) and young patients (<70 years of age)
for sorafenib and placebo. PRO was assessed at baseline and day
1 of each cycle using Functional Assessment of Cancer Therapy-
General (FACT-G) and FACT-Kidney Cancer Symptom Index
(FKSI). Descriptive statistics compared the proportion of patients
with a clinically meaningful change (4 point change) in total
scores of FKSI and Physical Well Being (PWB) from baseline.
Time to health status deterioration (4 point drop in total FKSI
scores or PWB scores of FACT-G) was assessed using Cox-
proportional Hazards model. RESULTS: A greater proportion of
patients in the sorafenib-treated group had improved or stable
symptom response and physical functioning in later cycles of
treatment, irrespective of age. Sorafenib delayed median time to
health status deterioration (as measured by FKSI questionnaire)
compared to placebo in elderly patients (121 days vs. 85 days)
The median time to health status deterioration as measured by
PWB domain of FACT-G was also longer for sorafenib compared
to placebo among elderly patients (126 vs. 84 days). A similar
trend was observed in younger patients. CONCLUSION: When
compared with placebo, elderly patients with advanced RCC
receiving sorafenib had PROs similar to those of young patients
receiving the same treatment, with both groups maintaining their
quality of life longer on sorafenib.
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OBJECTIVE: According to INCA (National Cancer Institute of
Brazil) estimates, colorectal cancer is the ﬁfth most common type
of cancer in the population; otherwise, it is the thirrd leading type
of tumor to cause death. The objective of this research is to assess
the knowledge of the Brazilian population about colorectal
cancer, its risks and diagnosis. METHODS: Quantitative study
performed through personal and individual interviews. A repre-
sentative sample of the study population (N = 600) was used.
People over 30 years old were interviewed. A 10-item structured
questionnaire was used. RESULTS: The study showed that 70%
of the population consider themselves as informed about cancer.
When asked about which would be the 3 most common types of
cancer, the main answers given were: 66% breast, 46% cervix,
42% prostate, 16% skin, and 15% lung. The colorectal cancer
was not mentioned by any subject in this question. Fifty-seven
percent of the population had never heard about colorectal
cancer. Among the 43% who had already heard about this type
of tumor, 76% didn’t know what were the symptoms and pre-
vention measures for this disease. Only 18% of the subjects over
50 years old have already undergone diagnostic tests for colorec-
tal cancer. CONCLUSION: Colorectal cancer is known for only
43% of the Brazilian population, which does not identify it as
one of the main tumors causing death in the country. In addition,
76% of the subjects who have already heard about this type of
cancer do not know the diagnostic and prevention methods for
this tumor. Only 18% of the population over 50 years old has
already undergone diagnostic tests for this type of cancer. These
results show that information campaigns about cancer could
render a better knowledge of the disease, which could result, in
the future, in early diagnosis, enabling a higher chance of cure
for patients.
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OBJECTIVE: Certain recent policy changes have mandated
ESA initiation at Hb < 10 g/dL. Real world clinical and eco-
nomic outcomes data associated with this change have not
been reported for the two FDA-approved ESAs for this popu-
lation [epoetin alfa (EPO) and darbepoetin alfa (DARB)].
METHODS: Data drawn between 12/03–11/07 from 55 U.S.
oncology clinics from the Dosing and Outcomes Study of
Erythropoietic Stimulating Therapies (D.O.S.E.) registry were
assessed. Patients were included if they were initiated on ESAs
with a BL Hb < 10 g/dL, age 18 years, and received 2 doses
of either EPO or DARB. Outcomes assessed included transfu-
sion utilization, Hb at Weeks 4, 8, 12 and 16 after ESA initia-
tion, and cumulative ESA doses with associated cost (based on
11/2007 wholesale acquisition cost). RESULTS: A total of 384
patients (168 EPO, 216 DARB) were identiﬁed. BL character-
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